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Abstract
Background: Fasciola hepatica is a liver parasite of mammals and it results in poor welfare outcomes and
economic losses in ruminants. While faecal egg count is the test most commonly used for diagnosis, it does not
indicate presence of migrating immature stages. Serological techniques increase sensitivity at all stages of the liver
fluke infection. The aim of this study was to compare four commercially available ELISA tests for the diagnosis of F.
hepatica. For this purpose, we tested three sample types; (i) known F. hepatica status sera from an experimental
infection for the comparison of sensitivities and specificities, (ii) sera from pre- and post-flukicide-treated
(albendazole, closantel, nitroxynil and triclabendazole) beef cattle to contrast the differences of seropositivity before
and after treatment, and (iii) bulk tank milk samples from dairy herds sampled during high and low F. hepatica
exposure periods for assessing seasonal variations with the four tests available. Samples were tested using ELISA kits
supplied by four manufacturers (Ildana Biotech, IDEXX, Svanova, and Bio-X). Samples were analysed simultaneously
and in duplicate.
Results: In the control population Ildana, IDEXX and Bio-X presented 100% sensitivity (Se) and specificity (Sp),
Svanovir presented a Se of 59% and a Sp of 96%. In flukicide-treated beef cattle, kits highlighted decreasing
antibody levels 90 days post-treatment in variable degrees. Finally, bulk milk showed a significant decrease in ELISA
value between high and low fluke exposure periods with all tests studied.
Conclusions: Se and Sp found in the present study, confirm that Ildana, IDEXX and Bio-X are accurate for the
detection of F. hepatica exposure in Irish cattle. Svanovir Se and Sp in this population, indicate that a larger study is
necessary to confirm this test characteristic in Irish herds. In post-treatment use, Bio-X showed a consistent and
significant decrease of ELISA value in all groups treated, denoting to be a reliable tool for assessing treatment effect
at 90 days post-treatment. Finally, all tests showed to be a reliable tool for the F. hepatica monitoring of high and
low exposure seasons, using bulk tank milk samples.
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Background
Fasciola hepatica, commonly known as the common
liver fluke, is a trematode parasite [1, 2] of mammals [3].
Its clinical manifestation is fasciolosis and it has a world-
wide distribution [4, 5] reflecting a marked capacity for
adaptation of both the causal agent and its intermediate
mollusc host [5]. This adaptability, combined with the
effects of global warming, increases the potential for F.
hepatica related losses in livestock [6, 7] and increased
prevalence in humans [5].
Fasciolosis is an important disease of domestic live-
stock [8] and both immature and mature stages of the
parasite in the final host result in a 15% decrease in milk
yield [9], an average reduction of 1.5 kg [10] or 0·7 kg
milk/cow per day [11]. Annual losses have been esti-
mated to be around €2.5 billion to livestock and food
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industry worldwide [12]. The presence of F. hepatica
may also impact the shedding of Escherichia coli O157
in cattle destined for the human food chain [13]. Al-
though livestock fasciolosis does not correlate with hu-
man fasciolosis [14], veterinary public health measures
and food safety practices are recommended to reduce
the risk of infection [5].
Fasciola hepatica has a preference for temperate cli-
matic zones as its 18 to 30 week life cycle [4] requires
mild temperatures and high humidity for the develop-
ment of the intermediate host and free-living stages
[15–18]. It can, however, also be found in areas of the
tropics in conjunction with Fasciola gigantica [14]. The
requirement for specific weather patterns for completion
of its lifecycle leads to seasonal variations in livestock in-
fection [19]. In temperate climatic zones without large
seasonal climatic variations such as Ireland, management
factors strongly influence the exposure and spatial distri-
bution of the parasite [20, 21].
The definitive diagnostic test for F. hepatica is liver
necropsy, which provides a highly accurate diagnosis of
fasciolosis when bile ducts are dissected [22]. This is not
practical as a herd or flock management tool as it can
only be carried out post-mortem [23]. The most fre-
quently used ante-mortem diagnostic test is the detec-
tion of eggs in faeces by sedimentation or flotation
techniques, which are expressed as faecal egg count
(FEC) [4] and had shown to have high specificity, detect-
ing current infection [24], however, the accuracy of de-
tection of small numbers of eggs in faecal samples is
determined by the volume of sample available [22, 25]
which constitutes a difficulty for diagnosis. The test can
also be a poor indicator of infection when the parasite
burden is low or when non-reproducing immature
stages are migrating [26, 27], although increasing sample
size and repeated sampling can increase both specificity
(Sp) and sensitivity (Se). These diagnostic tools are la-
borious, time consuming, require skills for the identifica-
tion of eggs and immature flukes, and are also
unsuitable for a large scale or herd level testing [27, 28].
To prove effective as part of a control programme,
diagnostic methods for herd screening must be reliable,
easy to perform [28], and the cost of testing must relate
to the benefit obtained by the diagnosis. Ideally, the
diagnostic test should allow for early diagnosis of infec-
tion, and have the capability to detect seasonal differ-
ences in infection thus informing treatment decisions
[29]. To meet these requirements, liver fluke specific
enzyme-linked immunosorbent assays (ELISA) have
been developed and are being routinely used in cattle
[19, 30, 31]. F. hepatica ELISAs are adaptable tests
which detect specific antibodies or antigens in faeces
and pooled or individual milk and sera. Failure to diag-
nose immature migrating stages of liver fluke in the final
host is a disadvantage of faecal egg counts, therefore the
use of ELISA tests with the capacity of early diagnosis is
a major advantage. The most damaging stage of this in-
fection in the final host occurs during the migration of
immature stages. The use of ELISA techniques for F.
hepatica diagnosis has demonstrated improved sensitiv-
ity of diagnosis over coprological techniques, and has
the improved advantage of detection of pre-patent infec-
tions [11, 31, 32]. Additionally, detection of F. hepatica
antigens in faeces is also feasible; using available copro-
antigen ELISA kits, which have shown to have high sen-
sitivity and specificity [31, 33].
At present, several F. hepatica ELISA kits for sera and
milk are commercially available, each comprising of dif-
ferent antigens, methods, sample dilutions, S/P% calcula-
tions and thresholds. Comparison of these tests under
identical conditions has not been previously assessed
and the wide range of commercial ELISA tests generates
indecision in the related community as to which test to
use and the significance of results. It is important to F.
hepatica management in cattle herds that commercially
available kits can not only detect infection but can do so
in a timely manner with the ability to detect seasonal
variations and post-treatment effects. The present study,
therefore, aimed to evaluate and compare four commer-
cially available ELISA kits for milk and sera, in their abil-
ity to detect exposure to F. hepatica in Irish cattle of
known status and in naturally infected herds; pre-and
post-flukicide treatment (sera), and in bulk tank milk
(BTM) samples taken over a 12 months period.
Results
Assay sensitivity and specificity
In all, 24 pre-colostral samples and 44 experimentally in-
fected samples (22 at four wpi and 22 at 10 wpi) were
tested across both groups. No liver fluke eggs were evi-
dent in experimentally infected calves at 4 weeks post-
infection. However, all infected calves recorded positive
FECs by 10 wpi and infected livers post-mortem (data
not shown).
Results from pre-colostral and experimentally infected
calves (4 and 10 wpi) across the four tests can be seen in
Table 2 and Fig. 1. Of the kits examined Ildana, IDEXX
and Bio-X correctly identified all 24 pre-colostral sam-
ples as negative and all 22 experimentally infected sam-
ples at both four and ten wpi as positive (Table 2). This
yielded Se and Sp for Ildana, IDEXX, and Bio-X kits of
100 and 100%, respectively, from at least four wpi
(Table 2). The Svanovir kit classified 23 of the 24 pre-
colostral samples as negative and 13 of 22 experimen-
tally infected samples at 4 and 10 wpi as infected with F.
hepatica with likely production losses (Table 2). This
yielded a Se of 59.1% and Sp of 95.8% for the Svanovir
test (Table 2).
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For all commercial kits examined, the number of posi-
tive and negative cases at four and ten wpi remained
consistent. However, variations in S/P% and ODRs were
observed principally in Ildana (P ≤ 0.0001), IDEXX (P ≤
0.0001) and Svanovir (P ≥ 0.05) (Fig. 1), although all
samples remained clearly positive. These variations in
Ildana and IDEXX were characterised by a decrease in
the range of positive S/P% (i.e. Ildana- 4wpi: 30 to 400%,
10wpi: 30 to 130%; IDEXX- 4wpi: 200 to 590%, 10wpi:
80 to 170%) (Fig. 1). In contrast, the Svanovir test
showed an increase in this range (4wpi: 0.4ODR to
0.8ODR, 10wpi: 0.4ODR to 1.5ODR), but this change
was not significant (Fig. 1). No evident or significant
changes were observed with the Bio-X kit.
Pre- and post-treatment kit variations in naturally
infected beef cattle
Ten animals were allocated to each treatment group and
in total 50 individual sera samples were tested on two
occasions (before and after the administration of a fluki-
cide treatment). A boxplot outlining pre- and post-
treatment results for each test kit across the five groups
investigated are included in Fig. 2.
Wilcoxon matched-pairs signed rank test for deter-
mining the significance of post- treatment variations de-
termined significance in nine of the 20 comparisons
(Table 3). The Bio-X test showed a decrease of S/P% in
albendazole (z = 2.85, P < 0.01), closantel (z = 2.67, P =
0.01), nitroxynil (z = 2.76, P = 0.01) and triclabendazole
(z = 2.76, P = 0.01) groups and for these groups, the de-
crease was observed in nine of the ten animals evaluated
(Table 3). In contrast, the Svanovir test only showed a
significant decrease of ODRs 90 days after albendazole
treatment (z = 2.40, P = 0.02) (Table 3).
Ildana and IDEXX tests detected an increase of S/P%
90 days after first sample in the no treatment group (z =
− 1.96, P = 0.05 and z = − 2.40, P = 0.02, respectively), this
increase resulted from six and nine animals, respectively.
Additionally, the Ildana test detected a significant de-
crease of S/P% in eight of the ten animals treated with
nitroxynil.
High and low exposure season detection in naturally
infected bulk tank milk samples
A total of 103 BTM samples from 29 herds were ana-
lysed using the four ELISA kits. In all, 14 herds supplied
samples for all 4 time points. The mean number of sam-
ples received per month was 26 samples (range 20 to
29). Herd sizes ranged from 60 to 310 milking cows, the
mean herd size being 157 cows. All study herds were
specialist dairy enterprises with no additional livestock
species such as fattening of cattle or sheep on the farm.
All cows were grazing from February until November
and were housed in December and January.
Fig. 1 Scatter plots outlining ELISA results from pre-colostral and experimentally infected calves (4 and 10 weeks post-infection (wpi)) across (a)
ILDANA, (b) IDEXX, (c) SVANOVIR and (d) BIO-X F. hepatica test kits. Positive cut-off values for each kit are represented by the dashed line (−---)
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Test results from the four ELISA kits revealed the
highest S/P% and ODR medians in December 2010 and
the lowest in July 2011 (Ildana (3.31 S/P%), IDEXX
(47.81 S/P%) and Svanovir (0.41 ODR)), the Bio-X test
showed the lowest S/P% in April 2011 (10.3 S/P%)
(Fig. 3).
Generalized estimating equation (Table 4) confirmed
the higher risk and lower exposure seasons observed in
the previous descriptive analyses. All tests showed sig-
nificant decreasing antibody levels in April, July and Oc-
tober against December. A decrease in July alongside
April was significant with the Ildana, IDEXX and Svano-
vir test (P = 0.006, < 0.001 and 0.021, respectively). A sig-
nificant decrease in S/P% was observed in October in
comparison to April using the IDEXX test (Coefficient =
− 27.04; P = 0.003), on the contrary the Svanovir test
showed a small significant increase (Coefficient = 0.09;
P = 0.044). Finally, higher S/P% were detected in farms
which treated with a flukicide in contrast with farms
which did not use any flukicide treatment.
Discussion
The aim of this study was to compare and evaluate four
commercially available ELISA kits (Ildana, IDEXX, Sva-
novir, Bio-X) for diagnosis of F. hepatica in Irish cattle,
as a comparative study of the four tests available has not
been previously reported. For this purpose, samples from
three different populations were evaluated, including
sera from a known-status population (known positive
and negative sera), sera from naturally infected beef cat-
tle (before and after treatment with different flukicides)
and naturally infected BTM samples from 31 dairy herds
(collected in four different months within a year). To
evaluate these tests a paired design was applied, offering
advantages like the minimisation of between-subject
variability and elimination of confounding [29]. Also, the
evaluation of these tests in naturally infected populations
gives a real view in day-to-day parasite control measures
practiced.
The Ildana assay is based on a recombinant antigen
[34] (Table 1) and has previously been used in multiple
Fasciola hepatica studies in Ireland [19, 21, 37]. Sensitiv-
ity and specificity ratios reported previously were 98% in
bovine sera [37]. Previous studies, which also used re-
combinant antigens, have reported similar sensitivities
and specificities at variable times post- infection [38–
40], and no cross-reaction with other present parasites
was observed [39]. The IDEXX kit (f2 antigen) (Table 1)
(originally the Pourquier ELISA) has shown to be very
reliable, as previous experimental infections reported
sensitivity and specificity ratios of 100% [38, 41] and
close to a 100% in natural infections [42, 43]. However, a
study by Simões et al. in 2017 reported a specificity ratio
of 56% in Brazil [44]. The E/S antigen, in the Svanovir
kit (Table 1), has previously shown a strong correlation
between F. hepatica antibody levels, intra-hepatic fluke
frequency and production parameters [11, 45] and a sen-
sitivity and specificity of 92 and 88%, respectively, in
BTM samples compared to sera [30]. With regards to
the Bio-X kit, containing the CL1 antigen (Table 1), an
earlier study found a strong correlation between an in-
house ELISA, which used the same antigen as Svanovir
(E/S), and Bio-X in sera from non-infected and naturally
infected cattle [46].
In the known status population all tests detected F.
hepatica antibodies 6 weeks prior to the detection of
Fig. 2 Boxplot of pre- and post-treatment results from naturally infected beef cattle across test kit and five flukicide treatments. Ildana, IDEXX and
Bio-X kits recorded results as S/P% (left Y axis) and the Svanovir kit recorded results as ODR (right Y axis). IL = Ildana Biotech Fasciola ELISA test kit.
ID = IDEXX Fasciola hepatica antibody test kit. SV = SVANOVIR Fasciola hepatica antibody test. BI = Bio-X Diagnostics Fasciola hepatica ELISA kit.
Pre = value prior to treatment i.e. Day 0. Post = value 90 days post-treatment i.e. Day 90
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Table 1 Summary of ELISA kit characteristics
ILDANA IDEXX SVANOVIR BIO-X
Coating
antigen
rmCL1 f2 E/S protein MM3
Antigen source Recombinant
[17]
Purified from natural F. hepatica
E/S products [34]
Purified from supernatant of F. hepatica
incubation media [35]
Purified from supernatant of F. hepatica
incubation media [36]
Sample types Serum, milk,
BTM
Serum, milk, BTM Serum, milk, BTM, meat juice Serum, milk, BTM
Serum sample
dilution
1/20 1/20 1/100 1/100
Milk sample
dilution
Not required 1/20 Not required 1/4
Total
incubation
70 min 110min 150min 130min
Optical density 450 nm 450 nm 405 nm 450 nm
Serum Positive
Cut-off
≥ 15S/P% > 30S/P% ≥ 0.4ODRa ≥ 10S/P%
aODR above which there is infection with liver fluke and likely associated production losses. Values below this cut-off indicate no or low fluke burdens
Fig. 3 Box plots of bulk tank milk ELISA results across test kit (a) Ildana, (b) IDEXX, (c) SVANOVIR, (d) BIO-X and time (December 2010, April 2011,
July 2011, October 2011)
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eggs by FEC. This early diagnosis has been widely de-
scribed in the literature [38, 41] and the present study
confirms this characteristic for the four different com-
mercial tests assessed. Ildana, IDEXX and Bio-X tests
presented a 100% Se and Sp in an experimental popula-
tion and is in line with sensitivity and specificity ratios
previously reported. Although the Svanovir test did not
reach the 100% Se and Sp it showed to be suitable for
the use with BTM samples for determination of in-herd
prevalence and seasonal changes. In the present study,
the Svanovir test detected one naïve animal as positive,
suggesting a possible attachment of unspecific antibodies
Table 2 Classification of samples from pre-colostral and experimental infected animals at 4 and 10 weeks post-infection (wpi) by
four commercial F. hepatica test kits
Assay Classification Exposed
4 wpi
Exposed
10 wpi
Not
exposed
Kit sensitivity
(%)
95% confidence
interval
Kit
specificity
(%)
95% confidence
interval
ILDANA Positive 22 22 0 100.0 84.6, 100.0
Negative 0 0 24 100.0 85.8, 100.0
Total 22 22 24
IDEXX Positive 22 22 0 100.0 84.6, 100.0
Negative 0 0 24 100.0 85.8, 100.0
Total 22 22 24
SVANOVIR Infected 13 13 1 59.1 36.4, 79.3
Low or no
infection
9 9 23 95.8 78.9, 99.9
Total 22 22 24
BIO-X Positive 22 22 0 100.0 84.6, 100.0
Negative 0 0 24 100.0 85.8, 100.0
Total 22 22 24
Table 3 Wilcoxon matched-pairs rank-signed analysis of individual cow pre- and post-treatment serum ELISA S/P values across four
test kits and five flukicide treatments
Test ILDANA IDEXX SVANOVIR BIO-X
Flukicide
treatment
Median Day 0
vs. Day 90a
Median Day 0
vs. Day 90a
Median Day 0
vs. Day 90a
Median Day 0
vs. Day 90a
z value P value z value P value z value P value z value P value
(n = 10) (n = 10) (n = 10) (n = 10)
No treatment 71.93 vs. 170.96 123.46 vs.282.60 0.54 vs.0.45 92.39 vs.83.23
−1.96 0.05 −2.40 0.02 2.05 0.04 1.69 0.09
6↑ 4↓b 9↑ 1↓ 2↑ 8↓ 4↑ 6↓
Albendazole 70.72 vs.51.38 81.13 vs.115.80 0.48 vs. 0.40 90.39 vs.67.87
0.36 0.72 −1.33 0.18 2.40 0.02 2.85 < 0.01
2↑ 8↓ 5↑ 5↓ 2↑ 8↓ 1↑ 9↓
Closantel 68.13 vs.1.09 104.96 vs. 66.07 0.57 vs. 0.37 100.30 vs. 30.11
0.09 0.93 1.51 0.13 1.78 0.08 2.67 0.01
3↑ 7↓ 4↑ 6↓ 4↑ 6↓ 1↑ 9↓
Triclabendazole 56.59 vs. 0 76.27 vs.15.26 0.49 vs. 0.46 68.06 vs.2.88
1.69 0.09 1.38 0.17 0.89 0.37 2.76 0.01
2↑ 8↓ 2↑ 8↓ 5↑ 5↓ 0↑ 10↓
Nitroxynil 78.32 vs.1.31 122.61 vs. 24.79 0.28 vs. 0.32 91.74 vs. 16.01
1.96 0.05 1.78 0.08 0.53 0.59 2.76 0.01
2↑ 8↓ 4↑ 6↓ 6↑ 4↓ 1↑ 9↓
aDay 90 indicates 90 days post-treatment with a particular flukicide
bIndicates the number of animals per group that either increased (↑) or decreased (↓) in S/P result
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to the antigen. Cross-reaction could only be possible in
the presence of other worm infections [38] and sera used
as known status- negative to F. hepatica were collected
from naïve animals, with no previous exposure to pas-
ture helminths (pre- colostral). This finding suggests
that further research needs to be conducted with this
test in Irish cattle as no previous reports of this finding
are available in the literature.
A decrease in S/P% was observed with the Ildana and
IDEXX kits (Fig. 1) at 10 weeks post-infection suggesting
final stages of the primary immune response [47],
however, further research is needed to confirm this. The
decrease in S/P% observed in the present study has pre-
viously been reported with IDEXX, with positive cases
still remaining positive after treatment [41] as in the
present study. But IDEXX has also shown to maintain
constant antibody detection after shorter periods of time
(21 to 42 days post- infection) depending on infection
dose [38]. In the present study, Svanovir and Bio-X
showed more stable S/P% and ratios at 10 weeks post-
infection (Fig. 1), the differences observed in ODR at 10
weeks post infection could be explained by variations in
Table 4 Generalized estimating equation analysis of bulk tank milk continuous ELISA results
Independent variable Coefficient
(n = 31)
Confidence interval
(95%)
P value Model
P value
ILDANA
April vs. December −24.21 −34.09, −14.32 < 0.001 Time
Herd size
Treatment
(< 0.001)
July vs. December −36.46 −46.37, −26.55 < 0.001
October vs. December −21.97 −32.30, − 11.65 < 0.001
July vs. April −12.25 −20.91, −3.59 0.006
October vs. April 2.23 −6.79, 11.25 0.628
October vs. July 14.48 5.42, 23.54 0.002
Treated vs. not treated 24.17 6.62, 41.72 0.007
IDEXX
April vs. December −36.22 −55.98, −16.47 < 0.001 Time
Herd size
Treatment
(< 0.001)
July vs. December −70.78 −90.57, − 50.98 < 0.001
October vs. December −63.27 −83.91, −42.63 < 0.001
July vs. April −34.55 −51.82, −17.27 < 0.001
October vs. April −27.04 −45.07, −9.02 0.003
October vs. July 7.50 −10.57, 25.58 0.416
Treated vs. not treated 29.69 −10.30, 69.69 0.146
SVANOVIR
April vs. December −0.19 −0.28, −0.10 < 0.001 Time
Herd size
Treatment
(< 0.001)
July vs. December −0.29 − 0.38, − 0.19 < 0.001
October vs. December − 0.10 − 0.20, − 0.01 0.036
July vs. April − 0.09 − 0.17, − 0.01 0.021
October vs. April 0.09 0.01, 0.17 0.044
October vs. July 0.18 0.09, 0.26 < 0.001
Treated vs. not treated 0.11 −0.04, 0.26 0.162
BIO-X
April vs. December −22.00 −31.54, −12.47 < 0.001 Time
Herd size
Treatment
(< 0.001)
July vs. December −18.75 −28.30, −9.20 < 0.001
October vs. December −16.41 −26.37, −6.45 0.001
July vs. April 3.25 −5.07, 11.57 0.444
October vs. April 5.59 −3.09, 14.28 0.207
October vs. July 2.34 −6.36, 11.05 0.598
Treated vs. not treated 30.07 20.29, 91.31 0.002
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the stability of the binding reaction between antigen and
antibody [48], however, further study would be needed
to confirm this observation.
As natural infections are usually constant during high
risk grazing periods [19], adult animals present higher
levels of detectable antibodies as they have been exposed
to more high risk seasons. Having said that, the experi-
mental infection method used in the present study in-
cluded a single infective dose, containing 115 METs and
was administered to young animals. Experimental infec-
tion does not necessarily equate the response measured
by these tests in adult cow populations, as adult cows
have been exposed repeatedly through their productive
lives, with the possible build-up of specific antibodies.
This is of special importance in pasture-based systems,
like Ireland.
In general, the naturally infected-beef population pre-
sented decreases of ELISA values 90 days after the appli-
cation of treatment. The Svanovir kit has previously
shown a significant decrease of ODRs at 3–6 months
[49] and 1 year [50] post treatment. These previous re-
ports and the present results propose the use of the Sva-
novir kit more than 90 days after treatment. In
comparison, results obtained from the Bio-X test con-
firmed that a 90 days period after treatment is adequate
to measure its effects.
In the naturally infected populations studied, the four
kits showed a general agreement in the detection of F.
hepatica antibodies in the different groups, this effect
was especially evident in the BTM population. The Sva-
novir test discrepancies seen in the known status popu-
lation were not evident in the BTM sample group, this
could be attributed to a larger sample size, the dilution
of antibodies in bulk tank milk samples [51] or higher
concentration of antibodies in adult animals.
Changes in BTMs antibody detection were dependent
on the seasonal exposure variations (Fig. 3 and Table 4),
as previously described in Europe [15], Germany [52]
and Ireland [19], which defined winter as high exposure
season and summer as low. Conventionally, ELISA test-
ing has been used with individual sera or even with
pooled sera for herd diagnosis. However, ELISAs are be-
ing widely used on BTM samples [19, 51] because of the
practicality for the determination of herd-level status,
making the BTM antibody ELISA an attractive alterna-
tive [30, 31]. The inconvenience of the use of ELISA
tests for the detection of F. hepatica antibodies is that
results do not necessarily indicate the presence of active
infection, as antibodies will still circulate after treatment
[51] and the levels of exposure would also be related
with age and stage of the milking period, it is important
to consider the treatment measures applied, age and
milking period of the herd before interpreting BTM
ELISA results. Nevertheless, the four tests studied
detected the classical seasonal dependent variations on
antibody levels in Irish dairy herds (Fig. 3).
Conclusions
It is clear that fasciolosis represents a major risk for the
health and production of cattle worldwide, moreover, a
potential increase of F. hepatica burden has been pre-
dicted as a result of climate change [7]. For the appro-
priate treatment and control of liver fluke, diagnosis is
key. As previously mentioned, the diagnostic test should
allow the early diagnosis of the disease, be able to detect
seasonal differences in infection and thus informing
treatment decisions [29]. The present study highlights
the early and reliable diagnostic capacity of the four
commercially available tests assessed for fasciolosis, al-
though, the Svanovir kit presented lower sensitivity and
specificity under experimental conditions. For a better
understanding of the Svanovir results in relation with
sensitivity and specificity, further studies need to be per-
formed using the Svanovir test in Irish cattle. All tests
detected changes in antibody levels 90 days post-
treatment and Bio-X showed greater accuracy in this de-
tection as all changes after treatment were significant.
However, a larger sample population and/or longer sam-
pling time would be necessary to confirm the findings
using the Svanovir kit as observed by Köstenberger et al.
in 2017 [50] and Charlier et al. in 2012 [49]. The use of
all four tests with BTM samples showed to be a reliable
tool for the determination of high and low exposure sea-
sons and in-herd prevalence throughout the year, how-
ever, results must be interpreted considering herd health
management, Fasciola hepatica life cycle and herd milk-
ing pattern.
Methods
Sample populations
Calves of known F. hepatica status – control population
To source negative samples of known F. hepatica status,
blood from 50 neonatal pre-colostral, housed calves born
in January and February 2016, were collected into plain
vacutainers. Calves were either Holstein-Friesian or
Jersey-cross breeds. All blood samples were collected
within the first hour post-calving. These calves were
born and housed at Teagasc (Irish Agriculture and Food
Development Authority), Moorepark, County Cork,
Ireland. Samples were collected by a parallel study under
license from the Health Products Regulatory Authority
(HPRA) (AE19132/P044) and approved by the Teagasc
Animal Ethics Committee (TAEC).
For the purposes of obtaining positive samples of
known F. hepatica status, blood samples were collected
from Holstein-Friesian calves (n = 25) experimentally in-
fected with F. hepatica metacercariae (MET). Experi-
mental infection was achieved by orally dosing each calf
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with 115 METs, after 10 weeks grazing period, this pre-
infection grazing period was carried out for acclimatisa-
tion and ensuring infection. Calves were housed imme-
diately post-infection. Grazing and housing took place at
Teagasc farm. These animals were infected as part of a
75-calf vaccination trial funded by the Irish Department
of Agriculture, Food and the Marine and licensed by the
HPRA (AE18982/P088) and TAEC. Only non-vaccinated
calves (control infected group) were included in the
current study. Blood and faecal samples were collected
on the fourth week post infection (wpi) for assessing the
detection of immatures stages and on the tenth wpi for
assessing mature parasites. For the purpose of post-
mortem evaluation, infected animals were transported
and slaughtered according to the Irish Slaughter of Ani-
mals Act [53] 3 months post-infection.
Naturally infected herds - blood
Blood samples were collected from a commercial beef
herd, containing animals of varying beef breeds, cross-
breeds and ages, located in county Clare, Ireland. This
herd recorded a prior history of F. hepatica infection by
ELISA diagnosis (data not shown). Animals were housed
for the winter months and grazed for the rest of the
year, the current experiment was carried out during the
housing period. Samples were initially collected and ana-
lysed for the purposes of evaluation of dosing strategies
in farmed beef in Ireland, and when archived, these sam-
ples were made available to the current study. Samples
were available from five different treatment groups;
albendazole (dose rate 10 mg per kg), closantel (dose
rate 10 mg per kg), nitroxynil (dose rate 10 mg per kg),
triclabendazole (dose rate 12 mg per kg) and a no treat-
ment control group. Individuals were randomly assigned
to each treatment group and each group contained 10
animals. Flukicides were administered based on body
weight estimates, on a single occasion, and administered
orally except for closantel which was a ‘pour on’ prepar-
ation. Blood samples were collected from the 50 individ-
uals prior to dosing (Day 0; February 2016) and again
90 days post-treatment (Day 90; May 2016); to allow
comparison of pre- and post-treatment ELISA results
under farming conditions in Ireland. The dosing strat-
egies experiment which supplied samples for the current
study was approved by the TAEC and licenced by the
HPRA (AE19132/P031) and funded by the Irish Depart-
ment of Agriculture, Food and the Marine.
Naturally infected herds - BTM
Archived bulk tank milk (BTM) samples were available
from 29 herds, 22 of which were commercial dairy herds
and members of the Dairy Management Information
System, a discussion group coordinated by Teagasc. The
remaining 7 herds were Teagasc dairy research herds.
Each herd was requested to submit four BTM samples;
in December 2010, April 2011, July 2011 and October
2011. Herd sizes and F hepatica dosing frequency and
active ingredient were available for each herd.
Sampling methods
Blood samples from neonatal calves were obtained by
jugular venepuncture. All other blood samples were col-
lected using venepuncture of the coccygeal vein. BTM
samples were collected by individual farmers and sub-
mitted to Teagasc by post in a standardised sampling kit
[19]. On receipt at the laboratory, blood and BTM sam-
ples were centrifuged (4000 g for 4 mins, blood; 20,000 g
for 1 min, BTM). Serum and skim BTM were subse-
quently collected into 1.5 mL microtubes and frozen at
-80 °C until analysed, ensuring only one freeze/thaw
cycle. Samples were obtained on the dates specified in
the sampling populations sections of the present study.
Faecal samples collected from the ground (faecal catch)
from the experimentally infected group were stored in
sample pots and analysed at the arrival to the laboratory.
Sample analysis
Five grams of faeces were homogenised with water and
passed first through a coarse mesh sieve and then a
finer, 250 μm mesh sieve. The filtrate was allowed to
stand for 5 min to sediment and the supernatant was re-
moved by aspiration. Sedimentation was repeated 1–2
times as required. The supernatant was removed and the
sediment was stained with two drops 1% methylene blue.
Eggs were counted on a stereomicroscope as outlined by
Taylor, et al., 2007 [4]. Results were expressed as pres-
ence or absence of liver fluke eggs and all samples were
evaluated by the same person.
Blood and BTM samples were analysed concurrently
using four commercially available ELISA kits; Ildana Bio-
tech Fasciola ELISA test (Ildana Biotech, Ireland),
IDEXX Fasciola hepatica antibody test kit (IDEXX,
France), Svanovir F. hepatica-Ab (Svanova, Sweden) and
Bio-X Diagnostics Fasciola hepatica Ab ELISA kit (Bio-
X Diagnostics, Belgium). All testing was carried out by
the same person. All kits have been validated by the
manufacturers for use with individual milk, pooled milk
and serum samples. Results for Ildana, IDEXX and Bio-
X kits were expressed as sample to positive percentage
(S/P%) and as optical density ratio (ODR) for the Svano-
vir test. The specific characteristics of each test are in-
cluded in Table 1. All assays were completed following
manufacturer’s instructions including calculation of S/
P% and ODRs.
Sample classification
In addition to continuous ELISA results, serological re-
sults were classified as positive or negative according to
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kit positive cut-off values for three kits (Ildana, IDEXX,
Bio-X). The fourth kit (Svanovir) classified samples
based on a cut-off value above which animals were
deemed infected and whether the potential for produc-
tion losses existed. These cut-off values are outlined in
Table 1 for each assay examined.
Two further categorisations of dairy herds were com-
pleted for bulk tank milk analyses. Firstly, herds were
classified as small (50 to 120 milking cows), medium
(121 to 190 milking cows) or large (over 190 milking
cows). These herd size ranges were defined to best rep-
resent the data recorded, generating categories of similar
size. Secondly, herds were classified on whether or not a
F. hepatica dosing protocol was applied in winter 2010.
Statistical analyses
Microsoft Excel (MS Office, 2010) was used for data col-
lation and initial descriptive analyses including scatter
plots. Assay Se, Sp and associated statistics were calcu-
lated using the MEDCALC diagnostic test evaluation
calculator (https://www.medcalc.org/calc/diagnostic_test.
php). Normality of the data was assessed by Shapiro-
Wilk normality test and visually using ladder of powers
histograms constructed in Stata version 12 (StataCorp,
USA). Boxplots, Wilcoxon matched-pairs signed-rank
test and Generalised estimating equations (GEE) were
completed using Stata version 12. GraphPad Prism 7
(GraphPad Software Inc., 2017) was used to construct
the box plot of natural infection-blood data.
Three databases were created, one for each sampling
population (known status, natural infection – blood and
natural infection – BTM). The Se and Sp of each kit was
calculated for each test using positive and negative sam-
ples of known status. Assay Se was calculated as the
probability that an experimentally infected calf would be
identified as positive (Ildana, IDEXX, Bio-X) or infected
(Svanovir) with F. hepatica, based on manufacturer’s in-
terpretation criteria. Sp was calculated as the probability
that a pre-colostral calf would be identified as negative
(Ildana, IDEXX, Bio-X) or not likely to have been ex-
posed to F. hepatica (Svanovir).
The naturally infected – blood data from beef cattle
were analysed by Wilcoxon matched-pairs signed rank
test to examine whether significant differences existed
between pre- and post-treatment groups across each
assay. Additionally, a boxplot was generated to allow
visualisation of results across both treatment and ELISA
kit used.
To examine whether trends in seasonality could be de-
tected using the assays under investigation, BTM data
(continuous) were analysed by GEE. For all continuous
GEE analyses, herd was included as a repeated measure
and an exchangeable correlation used. A Gaussian family
and identity link function was used. Independent
variables included in the analyses were herd size (small
vs. medium vs. large), dosing protocol (dosed vs. not
dosed in winter 2010), and time (December 2010 vs.
April 2011 vs. July 2011 vs. October 2011). These vari-
ables were forced into the model regardless of their sig-
nificance level due to their potential impact on BTM
results. Finally, results from herds that provided a
complete set of four BTM samples were plotted against
assay intermediate positive cut-off values to visualise
seasonality across assays.
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